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Abstract
Background: Mild Cognitive Impairment (MCI) is a disorder considered to be a transitional stage from
health to dementia. Diagnosis of dementias at these early stages is always troublesome because the
pathophysiologic events leading to dementia precede clinical symptoms. Thus, the development of
biomarkers that can be used to support the diagnosis of dementias at early stages is rapidly becoming a
high priority. We have recently reported the value of measuring plasmatic levels of neurosin in the
diagnosis of Alzheimer's disease (AD). The aim of this study is to determine whether measuring plasmatic
concentration of neurosin is a valuable test to predict progression of MCI.
Methods: Plasmatic neurosin concentrations were measured in 68 MCI patients and 70 controls subjects.
Blood samples were obtained at the beginning of the study. Sixty six patients diagnosed with MCI were
observed for 18 months. In 36 patients a second blood sample was obtained at the endpoint.
Results: The mean value of plasmatic neurosin concentration differs significantly between MCI patients
who converted to Dementia with vascular component, those who converted to AD, or those who
remained at MCI stage. The relative risk of developing Dementia with vascular component when neurosin
levels are higher than 5.25 ng/ml is 13 while the relative risk of developing mild AD when neurosin levels
are lower than 5.25 ng/ml is 2. Increases in the levels of neurosin indicate progression to Dementia with
vascular component.
Conclusion: The measurement of plasmatic neurosin level in patients diagnosed with MCI may predict
conversion from MCI to Dementia with vascular component. A single measurement is also valuable to
estimate the risk of developing A D  a n d  D e m e n t i a  w i t h  v a s c u l a r  component. Finally, repeated
measurement of plasmatic neurosin might be a useful test to predict outcome in patients with MCI.
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Background
Worldwide, the prevalence of dementia exceeds 24 mil-
lion people and, more importantly, current trends predict
that the number of people with dementia will double
every 20 years [1] increasing not only monetary cost in
medical terms, but also social awareness and concern
about these diseases. Currently, there are no laboratory
tests that allow distinguishing reliably different types of
neurodegenerative dementias and, therefore, their diag-
nosis remains based on clinical criteria once other "treat-
able causes" of dementia have been discarded. For these
reasons, increasing effort is invested in developing
biomarkers useful to precisely diagnose different types of
dementia, to allow diagnosis at earlier stages, and to mon-
itor progression of the dementia and response to treat-
ment. In this regard, peripheral fluids as source for
biological markers may be of great importance because of
their easy accessibility.
The pathophysiologic events leading to neurodegenera-
tion begin long before clinical symptoms arise but diag-
nosis at early stages is always troublesome. Patients with
mild cognitive impairment (MCI), a condition considered
a transitional stage from health to dementia, have
increased risk of developing AD [2] although they may, in
fact, develop any neurodegenerative disease or stay at the
same stage without further cognitive deterioration. The
identification of biomarkers to predict the onset of AD or
other dementias in presymptomatic patients is highly
important in critical practice because these diagnostic tests
could be extremely useful to improve diagnostic accuracy
and monitor the efficacy of putative therapies.
Human kallikreins are a multigene family of 15 secreted
serine-type proteases aligned in tandem in chromosome
19q13.4. Neurosin (Kallikrein 6) is a secreted "trypsin-
like" serine-protease mainly expressed in the brain [3-5].
Levels of neurosin in brain tissue, CSF, and blood are
altered in AD thus suggesting that measurement of neu-
rosin levels could potentially contribute to better diag-
nose dementias. Some of neurosin's substrates include
myelin basic protein, plasminogen, α1-antitrypsin, and
amyloid precursor protein (APP) [6,7]. Interestingly, neu-
rosin has been shown to cleave APP to generate amyloid
beta peptides [8].
In a previous study we measured plasmatic levels of neu-
rosin in healthy individuals and patients with cognitive
symptoms independently of what the final diagnosis was.
We found that plasmatic neurosin concentration increases
with age in healthy people and decreases in patients with
AD. We also showed that plasmatic neurosin concentra-
tion is lower in patients with AD than in patients with Vas-
cular Dementia [9].
The aim of the studies described in the current manuscript
was to determine whether measuring plasmatic concen-
tration of neurosin in MCI patients is a valuable test to
predict conversion to dementia.
Methods
This project has been approved by the Research and Ethics
Committees of the Hospital Universitario Central de Astu-
rias (HUCA). Informed consent was obtained from all
individuals or their guardians. We have followed the rec-
ommendations from the Standards for Reporting of Diag-
nostic Accuracy Group (STARD initiative) [10].
Patients
Screening
We screened patients assessed at the HUCA-Dementia
Unit who had symptoms suggestive of MCI.
Inclusion criteria
Patients suffering MCI according to Petersen's criteria
[11].
Exclusion criteria
Patients suffering from any kind of vascular or degenera-
tive dementia. Patients suffering from "treatable cognitive
impairment" including cancer (abnormal levels of kal-
likreins), hydrocephalus, deficiency or toxic disease, or
attributable to any other disorder. Renal or hepatic dys-
function (often associated with abnormal proteins levels).
Controls
Individuals without any central nervous system disorder
and ageing more than 60 years old were included as con-
trols. Controls were recruited among healthy people
matching the age of patients, mainly the spouses of the
patients included, or patients studied in our department
for peripheral nervous system diseases.
Clinical Assessment
All patients were studied with neuroimaging and full neu-
ropsychological assessment following the AAN recom-
mendations [12]. Neuropsychological assessment
included the "Test Barcelona Abreviado" [13] in all
patients as well as other tests depending on each patient's
profile. A functional scale (The Barthel Index) [14] was
also performed.
Follow-up
Patients were observed for 18 months with visits every 6
including functional assessment. Neuroimaging and full
neuropsychological assessment were performed again at
the endpoint and the diagnosis was reassessed.International Archives of Medicine 2008, 1:11 http://www.intarchmed.com/content/1/1/11
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ELISA to detect neurosin
The level of neurosin was determined at baseline in con-
trols and patients and at the endpoint in 36 patients using
ELISA (human kallikrein 6 research ELISA, IBEX, Canada)
following manufacturer's instructions. This test is based
on an assay previously described by Diamandis et al. [15].
Briefly, we performed a two step sandwich immunoassay
using recombinant neurosin as standard, a capture mouse
anti-neurosin monoclonal antibody and a mouse anti-
neurosin biotin-conjugated monoclonal antibody, both
within a stabilizing matrix including BSA. Bound bioti-
nylated antibody was detected with streptavidin-horserad-
ish peroxidase conjugate and tetramethylbenzidine as
substrate. The two anti-neurosin mouse monoclonal anti-
bodies used in this assay are specific for neurosin and
showed no cross reactivity against purified recombinant
human kallikrein 2, 3 (PSA), 5, 8, 10 and 13. Intra-assay
precision of this ELISA is CV ≤ 3.97 and inter-assay preci-
sion is CV ≤ 7.22. Standard curves were generated with
recombinant neurosin standard dilutions between 0.2
and 20 ng/ml.
Statistics
A Chi-square test was performed to study gender distribu-
tion differences between controls and patients. A T-Stu-
dent test was performed to assess differences in age
between controls and patients. A T-Student was per-
formed to assess differences between neurosin in patients
diagnosed with MCI and controls in the initial group.
ANOVA test and Bonferroni correction were performed to
asses the differences between the three groups after follow
up. A T-Student test was performed to assess the differ-
ences generated with time within every final diagnostic
group. Chi-square tests were performed to determine
whether there was an association between the occurrence
of clinical progression and the dichotomised plasmatic
levels of neurosin. Logaristic regression methods control-
ling gender and age were performed to determine the
probability of developing dementia in function of the
dichotomised plasmatic levels of neurosin.
Results
Sample description
We initially included in the study 70 control individuals
(29 males and 41 females) and 68 patients with MCI (21
males and 47 females). Eleven patients were screened but
excluded after assessment since they met one or more of
the exclusion criteria.
All patients and controls were Caucasian older than 60
years. To evaluate whether age or gender could be varia-
bles leading to misinterpretation of results, we analyzed
the composition of the two study groups. The results dem-
onstrated that there were no significant differences in gen-
der distribution (p = 0.760) nor in mean age (p = 0.454).
Diagnostic evolution of MCI patients
Sixty six patients with MCI were followed up 18 months
after diagnosis. The MCI did not progress in 30 cases
(45.4%). Twenty three patients (34.8%) developed AD
(according to the NINCDS-ADRDA criteria [16]) and thir-
teen patients (19.76%) developed Dementia with vascu-
lar component (probable or possible vascular dementia
according the NINCDS-AIREN criteria [17]). Therefore,
the conversion rate was 36.4% is per year.
Plasmatic concentration of neurosin in MCI patients and 
Controls
The mean value of plasmatic neurosin was not signifi-
cantly different (p = 0,348) between controls (mean: 5.52
ng/ml) and MCI patients at the beginning of the study
(mean: 5.97 ng/ml) (Table 1). However, the analysis of
the group of 66 patients that were followed up for 18
months shows that when we retrospectively calculated the
mean values of plasmatic concentration of neurosin in
MCI patients who converted to each group there were sig-
nificant differences between those who converted to
Dementia with vascular component (mean: 7.17 ng/ml),
those who converted to AD (mean: 4.96 ng/ml) (p =
0.015), and those who remained at MCI stage (mean: 5.03
ng/ml) (p = 0.036) (Figure 1). There were no differences
between those who did not convert and those who con-
verted to AD (p = 0.617).
Table 1: Plasmatic neurosin concentration in the final diagnostic groups.
Final Diagnosis Initial value (ng/ml) Final value (ng/ml)
N Mean N mean 95% confidence interval
MCI 30 5.03 (4.06–6.00) 6 5,56 (4.69–6.43)
AD 23 4.96 (4.08–5.84) 19 4,87 (4.42–5.32)
Dementia Vasc. comp. 13 7.17 (6.12–8.22) 11 8,79 (8.28–9.30)
Initial and final data of neurosin concentration for the three final diagnostic groups.International Archives of Medicine 2008, 1:11 http://www.intarchmed.com/content/1/1/11
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Evolution of plasmatic levels of neurosin predict outcome 
in patients with MCI
To determine whether time-dependent variation of plas-
matic levels of neurosin in patients with MCI is predictive
of outcome, we also measured plasmatic concentrations
of neurosin in 36 patients at the endpoint of the study
(Table 1 and Figure 2). The results showed that in only 18
months the levels of neurosin significantly increased
(from 7.17 ng/ml to 8.79 ng/ml) in patients whose dis-
ease progressed to dementia with vascular component (p
= 0.043) while the decrease in patients whose disease pro-
gressed to AD (from 4.96 ng/ml to 4.87 ng/ml) was not
statistically significant (p = 0.747).
Plasmatic levels of neurosin and risk of conversion
To further analyze these findings, we classified patients
according to their initial neurosin concentration in low (≤
5.25 ng/ml) or high (>5.25 ng/ml) (Table 2) and deter-
mined whether there is an association between disease
evolution and plasmatic levels of neurosin. We set the cut-
off at 5.25 ng/ml because it is the best cut point previously
determined by us to diagnose AD [9]. Results demon-
strated that, in patients diagnosed with MCI, there is an
association between the variable "developing Dementia
with vascular component" and a plasmatic concentration
of neurosin higher than 5.25 ng/ml (p < 0.001) as well as
an association between the variable "developing AD" and
a plasmatic neurosin concentration lower than 5.25 ng/
ml (p = 0.004). There is no association between "no con-
version" and dichotomised levels of neurosin (p = 0.437).
Then we calculated the probability of conversion. The risk
of developing Dementia with vascular component for
MCI patients with plasmatic neurosin higher than 5.25
ng/ml is 13.10 (with an interval 11.92–14.32 for a confi-
dence of 95%). The relative risk of developing AD in
patients with MCI and neurosin levels lower than 5.25 ng/
ml is 2.10 (with an interval 1.32 – 2.92 for a confidence
of 95%).
Discussion
It is now accepted that neurosin concentration in brain
tissue of patients with AD is decreased compared to nor-
mal individuals [18,19]. Whether the levels of neurosin in
CSF and plasma increase [20] or decrease [21,22] was an
active controversy. To address those discrepancies, we
Differences in plasmatic level of neurosin between the three diagnostic groups after follow up Figure 1
Differences in plasmatic level of neurosin between the three diagnostic groups after follow up. The plasmatic neu-
rosin concentration is shown for the three final diagnostic groups (MCI in green, AD in blue and Dementia with vascular com-
ponent in brown). Statistical differences were found between Dementia with vascular component and both AD and MCI.International Archives of Medicine 2008, 1:11 http://www.intarchmed.com/content/1/1/11
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recently studied plasmatic concentration of neurosin in
different types of dementia compared with normal indi-
viduals. We demonstrated that plasmatic levels of neu-
rosin increase in normal individuals as they get older [9].
More importantly, in that study we also demonstrated
that changes in plasmatic concentration of neurosin may
be valuable to predict outcome in certain types of demen-
tias.
We studied here whether measuring plasmatic concentra-
tion of neurosin may be a valuable test to predict progres-
sion of MCI. We measured plasmatic levels of neurosin in
controls and patients diagnosed with MCI. MCI patients
were followed for 18 months and then plasmatic concen-
trations of neurosin were measured again at the endpoint
in 36 patients (Table 1).
Our results, although preliminary, may be potentially very
significant in the prognosis of MCI for the following rea-
sons: 1) the mean value of plasmatic neurosin did not sig-
nificantly differ between MCI and controls but it differs
between patients with MCI who converted to Dementia
with vascular component and those who converted to AD
or remained at MCI stage. 2) Repeated measurement of
plasmatic neurosin is potentially a good parameter to pre-
dict progression in patients with MCI since there is a time-
dependent association between plasmatic levels of neu-
rosin and prognosis: increasing levels of neurosin are pre-
dictive of conversion to Dementia with vascular
component. 3) The risk of conversion is associated with
levels of neurosin: the relative risk of developing Demen-
tia with vascular component when neurosin level is lower
than 5.25 ng/ml is close to zero; however, the relative risk
of developing mild AD when neurosin levels are lower
than 5.25 ng/ml is 2. On the other hand, the relative risk
Evolution with time of the plasmatic level of neurosin Figure 2
Evolution with time of the plasmatic level of neurosin. Colour legend shows diagnostic groups after follow up. Vertical 
bars show standard deviation at baseline and final (after 18 months) points.
Table 2: Final diagnostic distribution after the 18 months follow 
up period.
>5.25 ≤ 5.25 P (χ2 test)
MCI 12 (40%) 18 (60%) 0.437
AD 7 (30%) 16 (70%) 0.004
DVasc.Comp 12 (93%) 1 (7%) <0.001
Patients initially diagnosed with MCI were followed up for 18 months. 
Data show final diagnostic distribution in relation to their initial 
plasmatic levels of neurosin (≤ or > 5.25 ng/ml) and the association (p) 
value.International Archives of Medicine 2008, 1:11 http://www.intarchmed.com/content/1/1/11
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of developing Dementia with vascular component when
neurosin level is higher than 5.25 ng/ml is above 13.
The mechanism by which plasmatic concentration of neu-
rosin increases in patients that convert to Dementia with
vascular component remains unknown. One possible
explanation is the interaction of neurosin with PARs (pro-
teinase-activated receptors). PARs comprise a family of G
protein-coupled receptors activated by thrombin or other
coagulation or inflammatory proteases released at sites of
tissue injury [23]. PARs are widely expressed in the CNS;
similar to hK6, the highest densities of PAR 2 were
observed in the hippocampus, cortex, amygdala, thala-
mus, hypothalamus, and striatum [24]. PAR 2 is activated
by neurosin [25,26]. Among other actions, PAR-2 induces
arterial and venous dilatation in vivo and therefore could
contribute to blood pressure dysregulation, which, in
turn, may account for the development of Dementia with
vascular component [27,28].
In conclusion, we report for the first time that measuring
plasmatic neurosin concentration may be useful to predict
conversion of patients diagnosed with MCI and we estab-
lished the relative risks of developing AD and Dementia
with vascular component according with the plasmatic
level of neurosin.
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